An experimental pill helped people lose up to 12 percent of their body weight in 36 weeks

An experimental daily pill helped people with obesity or excess weight shed as much as 12 percent of their body weight over 36 weeks, according to a trial that adds momentum to the search for a weight-loss drug that does not require an injection. The results are notable not only for the amount of weight lost but for the delivery method, because a once-daily tablet could reach far more people than the injectable medications that currently dominate the field.

What the trial measured

Researchers enrolled participants with obesity or overweight and randomly assigned them to receive the experimental drug at one of several doses or a placebo, taken once daily for 36 weeks. The design allowed the team to compare how much weight people lost at each dose against those taking an inactive pill, isolating the drug’s effect from the changes that come simply from being in a monitored study.

The central finding was that average weight loss reached roughly 12 percent at the higher end, with results across the dose groups ranging from a little under 10 percent to nearly 15 percent, compared with about 2 percent among those on placebo. That places the pill in the same broad territory as some injectable options, a comparison that matters because the medication belongs to the same drug class that has reshaped obesity treatment. Broader research has also linked GLP-1 drugs to heart benefits in high-risk patients, underscoring why the class draws such intense scientific interest.

How the drug works

The pill is a GLP-1 receptor agonist, a class of medications that mimics a hormone the body releases after eating. That hormone helps regulate blood sugar and signals fullness to the brain, which tends to reduce appetite and food intake. The injectable versions of this class have driven dramatic changes in obesity and diabetes care, and the experimental tablet aims to deliver a similar mechanism in a form people can swallow rather than inject.

Crucially, the drug is a small molecule, which distinguishes it from the larger, more complex injectable compounds. That chemistry is what allows it to survive being taken orally and, according to the researchers, could make it easier and cheaper to manufacture at the scale a mass-market obesity treatment would demand. It can also be taken with or without food, removing a practical hurdle that complicates some other oral therapies. Detailed results reported in coverage of the trial noted that the new GLP-1 pill delivered up to 12 percent weight loss in 36 weeks.

Why a pill could matter more than the numbers suggest

The weight-loss figures are impressive, but the format may prove more consequential. Injectable GLP-1 drugs have faced supply shortages, come with needle aversion for some patients, and require cold-chain handling that complicates distribution. A tablet sidesteps several of those obstacles. It is simpler to store and ship, more familiar to patients accustomed to taking pills, and potentially cheaper to produce, which could ease the access and affordability problems that have limited who benefits from the injectable versions.

Scale is the underlying issue. Obesity affects a very large share of adults, and the injectable drugs, for all their effectiveness, cannot easily reach everyone who might benefit. A manufacturable oral option could widen access considerably if it clears the remaining hurdles, changing the drugs from a constrained resource into something closer to a broadly available treatment.

The side effects and open questions

The trial reported that the most common adverse events were gastrointestinal, including nausea and related digestive symptoms, and that they were generally mild to moderate. That profile is consistent with the broader GLP-1 class, where stomach-related side effects are the usual complaint and often ease as the body adjusts or the dose is managed carefully. Even so, tolerability influences whether people stay on a medication long enough to benefit.

Important questions remain unresolved. The trial ran for 36 weeks, which leaves the long-term durability of the weight loss unproven, and obesity medications generally require ongoing use to maintain results, with weight often returning when treatment stops. How the pill performs over years, how well people tolerate it in everyday use rather than a controlled study, and how it compares head-to-head with established injectables are all questions that further research and regulatory review will need to answer.

Where this fits in a crowded field

The experimental pill enters a fast-moving area of medicine where several companies are racing to develop oral versions of drugs that have already transformed obesity and diabetes treatment in injectable form. Success would not be a single breakthrough so much as the removal of a major barrier, turning an effective but logistically demanding therapy into one that fits into the routine of taking a daily tablet.

For now the drug remains experimental, and its path to widespread use depends on longer studies and regulatory scrutiny. But a once-daily pill producing double-digit weight loss over roughly eight months signals that the next phase of obesity treatment may be defined less by how well the drugs work and more by how easily they can reach the people who need them.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview